Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age

Liver Transplantation

Volumn 16, Issue 7, 2010, Pages 837-846

  Tjon, Angela S W ^a   Sint Nicolaas, Jerome ^a   Kwekkeboom, Jaap ^a   De Man, Robert A ^a   Kazemier, Geert ^a   Tilanus, Hugo W ^a   Hansen, Bettina E ^a   Van Der Laan, Luc J W ^a   Tha In, Thanyalak ^a   Metselaar, Herold J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DE NOVO CANCER; FEMALE; GRAFT RECIPIENT; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; SKIN CANCER; AGE; BLOOD; GRAFT REJECTION; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; METHODOLOGY; MIDDLE AGED; MONITORING; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; MONITORING, PHYSIOLOGIC; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TACROLIMUS; YOUNG ADULT;

EID: 77954155767     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22064     Document Type: Article

References (51)

1. Mells G, Neuberger J. Long-term care of the liver allograft recipient. Semin Liver Dis 2009;29:102-120.
2. Neuberger J. Liver transplantation. J Hepatol 2000;32: 198-207.
3. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-815.
4. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2001;181:475-479.
5. Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008;14:1428-1436.
6. Jain A, Patil VP, Fung J. Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. Liver Transpl 2008;14:1406-1411.
7. Haberal AN, Suren D, Demirhan B, Bilezikci B, Celasun B, Haberal M. Evaluation of posttransplantation malignancies compared with de novo tumors. Transplant Proc 2007;39:1057-1062.
8. Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, et al. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005;11:89-97.
9. Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005;56:87-99.
10. Verdonk RC, van den Berg AP, Slooff MJ, Porte RJ, Haagsma EB. Liver transplantation: an update. Neth J Med 2007;65:372-380.
11. Buell JF, Brock GN. Risk of cancer in liver transplant recipients: a look into the mirror. Liver Transpl 2008;14: 1561-1563.
12. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-628. (Pubitemid 28098444)
13. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001;34:84-91.
14. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-S264.
15. Andre N, Roquelaure B, Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses 2004;63:647-652.
16. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001;7:971-975.
17. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80:1141-1150.
18. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6:1578-1585.
19. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
20. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44:1172-1181.
21. Kelly DM, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998;83:1237-1243.
22. Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clin Pharmacol Ther 1988;43:345-353.
23. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999;67:1133-1137.
24. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994;58:989-996. (Pubitemid 24356469)
25. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002;73: 953-959.
26. Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004;77:1632-1638.
27. Marin JG, Levine M, Ensom MH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients?Ther Drug Monit 2006;28:637-642.
28. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004;10:577-583.
29. Tha-In T, Hesselink DA, Tilanus HW, Elshove L, Wilschut AL, Hansen BE, et al. Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. Clin Transplant 2005;19:537-542.
30. Vereniging Intergrale Kankercentra (Comprehensive Cancer Center), Utrecht, The Netherlands. www.ikc.nl.
31. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996;62:599-606.
32. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-218.
33. Senel MF, Van Buren CT, Welsh M, Kahan BD. Impact of early cyclosporin average blood concentration on early kidney transplant failure. Transpl Int 1998;11:46-52.
34. Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994;26:2787-2790. (Pubitemid 24329317)
35. Ducloux D, Kazory A, Challier B, Coutet J, Bresson-Vautrin C, Motte G, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77:1029-1033.
36. Hibberd AD, Trevillian PR, Wlodarzcyk JH, Gillies AH, Stein AM, Sheil AG, et al. Cancer risk associated with ATG/OKT3 in renal transplantation. Transplant Proc 1999;31:1271-1272.
37. Santoyo J, Suarez MA, Perez-Daga JA, Fernandez Aguilar JL, Rodrigo J, Jimenez M, et al. Efficacy of C(2) monitoring of cyclosporine Neoral in adult liver transplantation: a comparative study. Transplant Proc 2001;33:3096-3097.
38. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomousmechanism. Nature 1999;397:530-534.
39. Shihab FS, Bennett WM, Isaac J, Yi H, Andoh TF. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003;63:522-533.
40. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003;76:597-602.
41. Sakai M, Miyake H, Tashiro S, Okumura Y, Kido H. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells. J Med Invest 2004;51:63-69.
42. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89:1221-1227.
43. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lympho-proliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289-1293.
44. Ben-Ari Z, Amlot P, Lachmanan SR, Tur-Kaspa R, Rolles K, Burroughs AK. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg 1999;5:184-191. (Pubitemid 29217988)
45. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236:429-436; discussion 436-427.
46. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002;8:939-944.
47. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996;2:52-59.
48. Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology (Carlton) 2006;11:355-366.
49. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70-78.
50. Timuragaoglu A, Ugur-Bilgin A, Colak D, Tuncer M, Golbasi I, Hazar V, et al. Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc 2006; 38:641-645.
51. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006;6:1017-1024.